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Atrial ﬁbrillation (AF) is the most common clinical
arrhythmia and is associated with increased risk for stroke,
heart failure, and all-cause mortality (1–3). The mortality
rate of patients with AF is about double that of patients in
normal sinus rhythm, and data from the Framingham Heart
Study show an AF-associated mortality risk even after
adjusting for preexisting cardiovascular conditions (3).
Although some of the mortality risk, such as stroke-related
death (4) and worsening heart failure, could be traced back
to AF, the fact remains that in most cases, AF is viewed
merely an association (5–8).
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In this issue of the Journal, Neilan et al. (9) provide
intriguing data that attempt to connect the dots between AF
and all-cause mortality. In this study, pre-ablation late
gadolinium enhancement (LGE) cardiac magnetic reso-
nance (CMR) images of 664 consecutive patients with AF
were analyzed for the presence of left ventricular (LV)
ﬁbrosis. None of the patients had a history of myocardial
infarction. In this otherwise low-risk cohort, 88 patients
(13%) had LV LGE on CMR. Furthermore, not only was
this unanticipated ﬁnding associated with increased
mortality, but the investigators also found a “dose effect”: the
larger the LGE, the worse the mortality.
Two obvious questions arise from this study: (1) What
comes ﬁrst, AF or LV ﬁbrosis? and (2) Are they independent
variables, or does one cause the other? Although no direct
evidence exists, circumstantial evidence suggests that AF
might be both the cause and subsequently the effect. AF has
been shown to affect LV systolic function by causing a rate-
related cardiomyopathy. In animal models, AF results in
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AF who are referred for catheter ablation, this statement is not
true especially in older patients with LV hypertrophy. Arterial
stiffness and LV diastolic dysfunction are often encountered
with older age and metabolic syndrome, which has been
associated with both AF and LV ﬁbrosis. In a longitudinal
follow-up of older patients with pacemakers who had
LV diastolic dysfunction and ﬁbrosis detected by echocar-
diographic acoustic densitometry, the incidence of newAFwas
correlated with the severity of LV ﬁbrosis, suggesting that
LV scar comes ﬁrst (11). In contrast, using T1 mapping,
Ling et al. (12) showed diffuse LV myocardial ﬁbrosis in
older patients with AF, suggesting abnormal LV remodeling
in AF. Focal LGE was also seen in 5 of 67 subjects (7%) in
this study.
Although mild interstitial ﬁbrosis is common in older
subjects, the onset of AF might accelerate the remodeling
process, which may in turn perpetrate AF. This vicious cycle
eventually will culminate in atrial and ventricular dysfunc-
tion, with or without focal or macroscopic LGE (13). The
propensity to develop LGE might be multifactorial and
might depend upon coronary perfusion, hypertension, dia-
betes, renal failure, and, last but not least, genetic factors that
regulate injury and repair. Whatever the reason, the very
ﬁnding of LGE on CMR appears to be not trivial and has
important consequences. The presence of LV myocardial
ﬁbrosis identiﬁed by LGE CMR imaging is an independent
predictor of adverse outcomes in various cardiomyopathies
(14,15).
In this study by Neilan et al. (9), patients with LGE were
on average older and more likely to have heart failure and
sleep apnea. Patients with LGE were also more likely to
have lower glomerular ﬁltration rates, lower LV ejection
fractions, and increased LV mass and/or left atrial dimen-
sions. Many of these comorbidities have been individually
linked to both AF and to myocardial ﬁbrosis. Unrecognized
coronary disease was also prevalent in this cohort. Because of
the confounders, which are well known to promote and
maintain AF, and at the same time to cause adverse LV
remodeling, the causal link between AF and LV ﬁbrosis is
difﬁcult to ascertain.
Yet another interesting question this study raises is the
optimal imaging modality to image the left atrium before AF
ablation. Noninvasive cardiac imaging plays an important
role in pre-procedural planning and guidance of the proce-
dures in many electrophysiology centers worldwide (16).
Multiple different techniques exist for anatomical imaging,
including angiography, computed tomography (CT), ultra-
sound, and CMR imaging. There are currently no guide-
lines, and the choice of imaging modality usually depends
on local expertise and available equipment. Both CT and
CMR imaging can provide accurate and detailed pulmonary
vein anatomy. LGE CMR imaging can provide additional
myocardial ﬁbrosis information, but CMR has less availability,
lower spatial resolution, and standard contraindications.
Cardiac CT is widely available and may also provide additive
Ling and Tandri JACC Vol. 62, No. 23, 2013
LV Scar in Atrial Fibrillation: Cause or Effect? December 10, 2013:2215–6
2216information beyond pulmonary vein anatomy. But CT is
associated with radiation exposure and has less evidence for the
identiﬁcation of myocardial ﬁbrosis. Neilan et al. (9) provide
a valuable reference for choosing CMR as the preferred image
modality before catheter ablation in certain groups of patients
with AF, especially in those who are older, have heart failure
or sleep apnea, have lower glomerular ﬁltration rates or LV
ejection fractions, and have increased LV mass or left atrial
dimensions. The ﬁnding of LGE in the left ventricle might
identify patients with occult coronary disease or cardiomyop-
athy or trigger aggressive risk factor management of modiﬁable
risks such as sleep apnea and hypertension. Whether this
strategy will better risk-stratify patients at risk for mortality
and thus change the observed outcomes needs to be tested
in prospective studies designed speciﬁcally to answer this
question.
Patients who undergo pulmonary vein isolation are just
the tip of the AF iceberg, and those patients who are
screened and are thought not to be good candidates for
pulmonary vein isolation because of persistent AF with
severe comorbidities are very likely to harbor LV ﬁbrosis.
The logical next step would be to investigate both the
prevalence of LV LGE and its association with cardiovas-
cular mortality in this enriched group. Further studies are
needed to establish whether LGE is a major independent
predictive factor of cardiovascular mortality in patients with
AF.
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